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Abstract 
Human growth factor receptor-bound protein-7 (GRB7) is a pivotal mediator involved in receptor tyrosine 
kinase signaling and governing diverse cellular processes. Aberrant upregulation of GRB7 is frequently 
associated with the progression of human cancers. However, the molecular mechanisms leading to the 
upregulation of GRB7 remain largely unknown. Here, we propose that the epigenetic modification of GRB7 at 
the post-transcriptional level may be a crucial factor leading to GRB7 upregulation in ovarian cancers.  
Methods: The upstream miRNA regulators were predicted by in silico analysis. Expression of GRB7 was 
examined by qPCR, immunoblotting and immunohistochemical analyses, while miR-193a-3p levels were 
evaluated by qPCR and in situ hybridization in ovarian cancer cell lines and clinical tissue arrays. MS-PCR and 
pyrosequencing analyses were used to assess the methylation status of miR-193a-3p. Stable overexpression or 
gene knockdown and Tet-on inducible approaches, in combination with in vitro and in vivo tumorigenic assays, 
were employed to investigate the functions of GRB7 and miR-193a-3p in ovarian cancer cells. Results: Both 
miR-193a-3p and its isoform, miR-193b-3p, directly targeted the 3’ UTR of GRB7. However, only miR-193a-3p 
showed a significantly inverse correlation with GRB7-upregulated ovarian cancers. Epigenetic studies 
revealed that methylation-mediated silencing of miR-193a-3p led to a stepwise decrease in miR-193a-3p 
expression from low to high-grade ovarian cancers. Intriguingly, miR-193a-3p not only modulated GRB7 but 
also ERBB4, SOS2 and KRAS in the MAPK/ERK signaling pathway to enhance the oncogenic properties of 
ovarian cancer cells in vitro and in vivo. Conclusion: These findings suggest that epigenetic silencing of 
miR-193a-3p by DNA hypermethylation is a dynamic process in ovarian cancer progression, and miR-193a-3p 
may be explored as a promising miRNA replacement therapy in this disease. 
Key words: DNA hypermethylation, miR-193a-3p, GRB7, MAPK signaling, ovarian cancer. 
Introduction 
Ovarian cancer is one of the most lethal 
gynecological malignancies. Most ovarian cancer 
cases have a poor prognosis and exhibit a highly 
lethal rate at an advanced stage. High-grade ovarian 
cancers have a particularly poor prognosis and are 
extremely aggressive. An understanding of the 
molecular mechanisms, such as the characterization of 
genetic/epigenetic alterations of oncogenes/tumor 
suppressor genes, could, therefore, facilitate the early 
diagnosis and treatment of this highly malignant 
disease. 
Growth factor receptor bound protein 7 (GRB7) 
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is an adaptor protein that plays an important role in 
mediating signal transduction from multiple cell 
surface receptors to various downstream signaling 
pathways. Emerging evidence indicates that GRB7 is 
overexpressed in multiple human cancers, usually 
accompanied by the overexpression of ErbB2 [1, 2]. 
Clinicopathological analyses have shown that 
overexpressed GRB7 is correlated with a metastatic 
phenotype [1, 3]. Overexpression of GRB7 enhances 
the migration ability of cancer cells. Thus, GRB7 may 
be used as a potential tumor marker or therapeutic 
target for therapeutic purposes [4, 5]. Conversely, 
inhibitors of GRB7 are currently used preclinically for 
the treatment of cancers [6]. One promising anti-GRB7 
peptide, G7-18NATE, can bind to the GRB7 SH2 
domain specifically [3, 7]. This inhibitor can prevent 
GRB7 from binding to other activated tyrosine kinases 
[7]. Indeed, SKBR3 and ZR-7530 drugs can exert 
significant inhibition of cell growth and migration in 
ErbB2-positive breast cancer [3, 8]. These reports 
provide strong evidence that GRB7 can be used as a 
tumor marker and a promising target for cancer 
therapy. We have previously reported that GRB7 and 
its isoform, GRB7v, are overexpressed and associated 
with high-grade ovarian cancers [9]. Akin to other 
human cancers, GRB7 promotes cell proliferation, cell 
migration and cell invasion, while GRB7v only 
increases cell proliferation and cell 
anchorage-independent growth capacities [9]. With 
the treatment of specific kinase inhibitors, we 
demonstrated that both GRB7 and GRB7v are 
associated with high-grade tumors and exert distinct 
tumorigenic functions by regulating different 
signaling pathways in ovarian cancer cells. However, 
the underlying mechanism leading to overexpression 
of GRB7 remains unclear. 
MicroRNAs (miRNAs) are a class of small 
noncoding RNAs (19-25 nucleotides) that enable 
negative modulation of the expression of 
protein-coding genes by binding, with imperfect base 
pairing, to complementary sequences of target sites in 
messenger RNAs (3' untranslated regions, 3’-UTR) 
with the RNA induced silencing complex (RISC) [10, 
11]. This phenomenon leads to a global regulation of 
gene expression in cells [12]. In this study, we found 
that the GRB7 protein levels were remarkably higher 
than their mRNA levels in some ovarian cancer cell 
lines, indicating that there is an aberrant 
post-transcriptional alteration in GRB7. In an in silico 
study using 3 bioinformatics algorithms, we 
discovered that miR-193a-3p directly regulates GRB7 
but is usually downregulated by DNA 
hypermethylation during ovarian cancer 
development and progression. The epigenetic 
silencing of miR-193a-3p leads to the aberrant 
upregulation of GRB7 and related oncogenes in 
MAPK/ERK signaling. Our study provides insights 
into the development of miR-193a-3p as a 
miRNA-based oncological therapeutic approach for 
targeting MAPK/ERK signaling to treat human 
ovarian cancer. 
Materials and Methods 
Cell lines and Human tissues 
The human ovarian cancer cell lines TOV21G, 
SKOV3, ES-2, and HEK293 were purchased from the 
American Type Culture Collection (ATCC). OVISE 
and OVTOKO were purchased from the National 
Institute of Biochemical Innovation, JCRB Cell Bank. 
Two ovarian cancer cell lines, A2780s and A2780cp, 
were kindly provided by Prof. Benjamin K Tsang, 
University of Ottawa. Additionally, three human 
ovarian cancer cell lines, OVCA420, OVCA429 and 
OVCA433, as well as two humans immortalized 
ovarian surface epithelial cell lines (HOSEs), HOSE11 
and HOSE96, were kindly provided by Prof. Georg 
SW Tsao, The University of Hong Kong. All cell lines 
were cultured in DMEM or RPMI 1640 medium 
(Sigma-Aldrich Corp., St. Louis, MO, USA) containing 
10% fetal bovine serum (Invitrogen) and incubated in 
5% CO2 at 37 °C. All cell lines were authenticated by 
in-house STR DNA profiling analysis, and 
mycoplasma contamination was tested. The clinical 
ovarian cancer patient samples were collected from 
the Queen Mary Hospital (Hong Kong) and 
immediately snap-frozen in liquid nitrogen and 
stored at −80 °C. Written informed consent was 
obtained from the participants, and the study was 
approved by Institutional Review Board of the 
University of Hong Kong/Hospital Authority Hong 
Kong West Cluster (HKU/HA HKW IRB) 
(Institutional Review Board number: UW11-298). 
Plasmids and cell transfection 
The miR-193a-3p and miR-193b-3p-expressing 
constructs were established by PCR amplification of 
genomic DNA and ligated into the pmR-ZsGreen1 
plasmid (Clontech, Mountain View, CA) to generate 
pmR-ZsGreen1-miR-193a-3p or pmR-ZsGreen1-miR- 
193b-3p plasmids. The PCR DNA fragment 
containing miR-193a-3p precursor was also subcloned 
into pmRi-mCherry vector to generate the inducible 
miR-193a-3p expression construct pT-193a. The 
GRB7-expressing plasmid pEGFP/GRB7 was 
reported previously [9], and pCMV6-GRB7 was 
generated by subcloning the GRB7 full-length cDNA 
fragment from a Puc57-GRB7 plasmid (purchased 
from BGI-Shenzhen, China) into pCMV6-Entry vector 
(Origene). The SOS2-expressing plasmid (pCGN- 
SOS2) was obtained from Addgene (plasmid# 32921). 
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Lipofectamine 3000 (Invitrogen) was used for cell 
transfection following the protocol. Stable ovarian 
cancer cells overexpressing miR-193a-3p were 
harvested after 14 days of G418 selection and verified 
by QPCR. Ovarian cancer cells with stable GRB7 
knockdown were infected with lentiviral particles 
carrying GRB7 shRNA plasmid (Santa Cruz). After 
puromycin selection for 1 week, the stable GRB7 
knockdown cells in the pool were verified by Western 
blot analysis. The double-stable doxycycline-inducible 
miR-193a-3p system was established according to the 
manufacturer's instructions using the Mir-X Inducible 
miRNA System (Clontech). Surviving Tet-On-miR- 
193a single clones were selected, expanded and 
screened for doxycycline-induced (1 μg/ml, Clontech) 
miR-193a-3p expression by QPCR. 
RNA isolation and Quantitative RT-PCR 
Total RNA was extracted from cell lines and 
human tissue samples using TRIzol reagent 
(Invitrogen Life Technologies, Carlsbad, CA, USA). 
First-strand complementary DNA was synthesized 
with a universal cDNA Synthesis Kit (Exiqon, 
Denmark). miRNA quantification by real-time PCR 
was performed using miRCURY LNA™ Universal RT 
microRNA PCR (Exiqon). Prime sets obtained from 
Exiqon included hsa-miR-193a-3p (Product No. 
204591), hsa-miR-193b-3p (Product No. 204226) and the 
internal normalization control SNORD48 (Product 
No. 203903). Each sample was run in triplicate on a 
ViiA 7 Real-Time PCR System (Thermo Scientific). 
Methylation-specific PCR (MS-PCR) and 
Pyrosequencing analysis 
Genomic DNA was extracted from cell lines or 
clinical samples using the Wizard Genomic DNA 
Purification Kit (Promega). The DNA was then 
modified with sodium bisulfate using the EZ DNA 
Methylation-Gold Kit (Zymo Research, Orange, 
California, USA) following the protocol described by 
the manufacturer. The MS-PCR primers were 
designed using MethPrimer software and used to 
amplify and determine the specific methylated region 
on genomic DNA by DNA MyTaq TMHS Mix Reaction 
Buffer (Bioline, London, UK). A pyrosequencing assay 
was performed to detect the methylated CpG islands 
within an 800-bp region in the advanced miR-193a-3p 
at the Centre for Genome Sciences of The University 
of Hong Kong. Primers for pyrosequencing were 
designed using PSQ Assay Design Software (version 
1.0.6, Biotage). 
Western Blot analysis 
Cells were harvested and lysed in cell lysis 
buffer (Cell Signaling technology, #9803) and 
analyzed by Western blotting as described previously 
[13]. Antibodies against ERBB4 (4795, Cell Signaling), 
GRB7 (sc-13954, Santa Cruz), KRAS (ab180772, 
Abcam), SOS2 (ab137199, Abcam), ERK (4795, Cell 
Signaling), phosphorylated ERK (4795, Cell Signaling) 
and β-actin (1:10000, AC-74, Sigma Chemical Co) 
were used. 
Immunohistochemistry (IHC) and in situ 
hybridization (ISH) 
The commercial ovarian cancer tissue array 
(OVC1021) was purchased from Pantomics 
(Pantomics Inc., San Francisco, CA). The slides were 
incubated with the primary polyclonal anti-GRB7 
antibody (H70, Santa Cruz Biotechnology, Inc.) at a 
1:50 dilution. Further details of the procedure have 
been described previously [13]. In situ hybridization 
(ISH) was performed with the miRCURY LNATM 
microRNA ISH Optimization Kit 5 (FFPE) (Exiqon) to 
detect the expression of miR-193a-3p according to the 
manufacturer's instructions. 
Proximity ligation assay (in situ PLA) 
The proximity ligation assay (in situ PLA) was 
carried out using the Duolink in situ PLA kit 
(Sigma-Aldrich) according to the manufacturer's 
protocol. Briefly, SKOV3 cells were grown on 
chamber slides and transfected with 
pCMV6-MYC-GRB7 or pCGN-HA-SOS2 constructs. 
Transfected cells were then fixed, permeabilized and 
blocked in blocking solution in a humidified chamber 
for 1 hour at 37°C. Mouse anti-Myc (Sigma-Aldrich) 
or mouse anti-HA (Santa Cruz Biotechnology) with 
appropriate anti-rabbit primary antibodies (ERBB4, 
SOS2 or KRAS) were added at a 1:200 dilution in 
antibody diluent and incubated overnight at 4°C. 
After Duolink® PLA probe incubation, ligation and 
amplification, the slides were embedded in Duolink® 
in situ mounting medium with DAPI, and images 
were acquired using a Carl Zeiss LSM 800 confocal 
microscope. 
Luciferase reporter assay 
Luciferase constructs were created by ligating 
part of the 3’UTR sequences containing the potential 
miR-193a-3p binding sites of ERBB4, GRB7, KRAS and 
SOS2 genes into the pmirGLO plasmid (Promega, 
Madison, WI) (Supplementary Fig. S2). HEK293 cells 
were seeded into a 24-well plate and cotransfected 
with the pmirGLO-3’UTR plasmid of the above 
plasmids or vector control using LipofectamineTM 
3000 (Invitrogen). Luciferase activities were detected 
using the Dual-Luciferase Assay Kit (Promega). 
Cell viability assay, in Vitro cell migration and 
invasion assays 
Cell viability was determined using an XTT 
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assay. Briefly, approximately 1,000 - 2,000 cells were 
subcultured in a 96-well plate. XTT was measured at 
days 0, 1, 2 3 and 4 post-plating using the Cell 
Proliferation Kit II (Roche Biosciences, Indianapolis, 
IN, USA). Cell migration and invasion assays were 
performed using Transwell cell migration assay kits 
(Corning, New York, NY, USA) and BioCoat™ 
Matrigel® Invasion Chambers (Corning), 
respectively. For doxycycline-induced miR-193a-3p 
expression, cells were pretreated with or without 1 
μg/ml doxycycline. After 48 h, the cells were 
trypsinized and placed in the upper chamber filled 
with serum-free culture medium with or without 
doxycycline (1 μg/ml) and allowed to migrate or 
invade. 
In vivo tumorigenicity 
Four-week-old BALB/C-nu/nu female mice 
were used for intraperitoneal injection. SKOV3 cells 
stably expressing the Tet-On-miR-193a in pT-193a or 
vector control, SKOV3 with the GRB7 stable 
knockdown clone or the scrambled control (2× 106) 
were injected into nude mice (N = 5 per group) as 
described previously [13]. For inducible miR-193a-3p 
expression, nude mice in each group received 2 
mg/ml doxycycline via the drinking water for 20 
days. Drinking water containing doxycycline was 
changed every two days for the 4-week period of 
tumor regression. All mice were sacrificed on Day 60 
after injection of the cells. All animals were housed 
and handled experimentally according to the 
guidelines approved by the Committee on the Use of 
Live Animals in Teaching and Research of The 
University of Hong Kong CULATR 3960-16. 
Statistical analysis 
Unless otherwise stated, all experiments were 
verified at least three independent times. Values are 
presented as the mean ± SEM, and the 2-tailed 
Student’s t test was used for comparisons. Data were 
plotted using GraphPad Prism 6 software (GraphPad 
Software, Inc., CA, USA). Statistical analyses were 
carried out with SPSS software (version 16.0). A 
receiver operating characteristic (ROC) curve was 
used to determine the cut-off points for the ISH and 
IHC data. The Fisher’s exact test (for parametric data) 
and the Mann–Whitney test (for non-parametric data) 
were used. P≤ 0.05 was considered significant.  
Results 
Loss of miR-193a-3p is attributed to 
overexpression of GRB7 in ovarian cancer cells 
GRB7 is localized in the 17q12 locus, and its 
amplification has been reported in numerous human 
cancers [14, 15]. Based on the Cancer Genome Atlas 
(TCGA) data sets in cBioPortal (www.cbioportal.org), 
the results also indicated a higher expression rate of 
GRB7 in ovarian cancer compared with other tumor 
sets (Fig. 1A). These data were corroborated by our 
previous study [9], in which we found that GRB7 and 
its isoform, GRB7v, were overexpressed and 
associated with high-grade ovarian cancers [9]. 
Further analyses showed that both GRB7 and GRB7v 
promoted cell proliferation by activating the 
MAPK/ERK signaling pathway [9]. However, we 
found a disparity in the expression of GRB7 protein 
and mRNA by real-time quantitative RT-PCR (qPCR) 
and Western blot analyses of a panel of ovarian cancer 
cell lines, suggesting an aberrant post-transcriptional 
alteration in GRB7[9]. 
In this in silico study using 3 bioinformatics 
algorithms, miRDB, miRanda, and TargetScan 
Human 5.2, we identified miR-193a-3p and its isoform, 
miR-193b-3p, by specifically targeting the same 
conserved site (GGCCAGT) at position 332–338 in the 
3’ UTR (length: 3894 of the human GRB7 gene 
(NM_001030002) (Fig. 1B & 1C). Using Western blot 
and qPCR analyses, we found that the miR-193a-3p 
and GRB7 levels in most ovarian cancer cells lines, as 
well as HOSEs, were inversely correlated, whereas the 
levels of miR-193b-3p were higher than HOSEs in all 
ovarian cancer cells and had a lower correlation with 
GRB7 protein levels (Fig. 1D & 1E). Of note, the 
expression of GRB7 was low in some ovarian cancer 
cell lines, such as OVCA429, A2780s and OVTOKO, 
which had relatively low levels of miR-193a-3p. 
However, we found that these cell lines had relatively 
high levels of miR-193b-3p (Fig. 1D & 1E), which 
indicated that both miR-193a-3p and miR-193b-3p 
exerted an equivalent translational suppression effect 
on GRB7 because they had the same binding site in 
the 3’UTR of GRB7 (Fig. 1C). Indeed, transient 
transfection of either miR-193a-3p or miR-193b-3p into 
SKOV3 or OVCA433 cells could remarkably reduce 
GRB7 expression in a dose-dependent manner (Fig. 
1F). However, based on the expressions pattern of 
both miR-193a-3p and miR-193b-3p versus the protein 
level of GRB7 in ovarian cancer cell lines and HOSEs, 
the downregulated miR-193a-3p seemed to play a 
more important role in GRB7 post-transcriptional 
regulation. 
To validate the post-transcriptional suppressive 
effect of miR-193a-3p, we employed a luciferase 
reporter assay with the wild-type and mutant 3’UTR 
of GRB7. The results showed that pmiR-193a-3p could 
significantly attenuate the signal from the luciferase 
reporter fused to the wild-type miR-193a-3p target 
sequence (GGCCAGT) of the GRB7 3'UTR compared 
with the empty vector control (Fig. 1G). Conversely, 
this suppressive effect was absent in the miR-193a-3p 
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target mutant (AACCAAT) (Fig. 1G). This finding 
indicated that GRB7 was the target of miR-193a-3p and 
that the upregulation of GRB7 was attributed to the 
loss of miR-193a-3p in ovarian cancer cells. 
 
 
Figure 1. The expression of miR-193a-3p is downregulated and inversely correlates with GRB7 expression in ovarian cancers. (A) Comparison of GRB7 expression in human ovarian cancer 
with other tumor types using the cBioPortal database. The dots represent clinical cases, and the line in the upper and lower box plot represents the upper and lower quartile of the relative 
mRNA levels of all samples. (B) The Venn diagram shows miR-193a-3p and miR-193b-3p commonly predicted by miRDB, TargetScan, and Miranda. (C) A schematic diagram showing the same 
binding site of miR-193a-3p and miR-193b-3p at position 332-338 of human GRB7 3' UTR. (D) Western blot analysis of GRB7 expression in ovarian cancer cell lines and HOSEs. (E) qPCR 
analysis of miR-193a-3p (upper) and miR-193b-3p (lower) expression in ovarian cancer cell lines. SNORD48 was used as an internal control. (F) Western blot analysis showing that transient 
transfection of pmR-ZsGreen1-miR-193a-3p or pmR-ZsGreen1-miR-193b-3p reduced the expression of GRB7 in SKOV3 or OVCA433 cells in a dose-dependent manner. (G) A schematic 
diagram showing the putative miR-193a-3p binding site in wild-type and mutant GRB7 3’UTR (Upper). Luciferase reporter assay showing the relative luciferase activity of wild-type or mutant 
GRB7 3’UTR targeted by a miR-193a-3p using pmR-ZsGreen1-miR-193a-3p plasmid in HEK293 cells (Lower). 
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MiR-193a-3p suppresses not only GRB7 but 
also MAPK/ERK signaling in ovarian cancer 
cells 
It is well known that a single miRNA can 
modulate a cohort of downstream gene targets. 
Hence, to examine other putative downstream targets 
of miR-193a-3p that may mediate the oncogenic 
capacities of ovarian cancer cells, and in silico study 
using three bioinformatics algorithms (miRDB, 
miRnada and TargetScan) was applied and identified 
78 potential genes (Fig. 2A) (Supplementary Table S1). 
Among these potential targets, MAPK/ERK signaling 
was the dominant signaling pathway in cancers by 
KEGG (Kyoto Encyclopedia of Genes and Genomes) 
according to the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) (Fig. 
2B). ERBB4, SOS2 and KRAS have been defined as key 
components of this signaling pathway for modulating 
ERK activity [16] (Supplementary Fig. S3). The 
formation of the GRB2–SOS complex and the 
conversion of GDP to GTP through interactions with 
RAS are crucial steps in the activation of the 
MAPK/ERK signaling cascade [17, 18]. Consistently, 
by employing a proximity ligation assay (in situ PLA), 
GRB7 was shown to directly interact with endogenous 
SOS2 and KRAS in the cytosol of OVCA433 though 
transient transfection of Myc-tagged GRB7-expressing 
plasmid and anti-Myc plus either anti-SOS2, 
anti-KRAS or anti-ERBB4 antibodies (Fig. 2C). 
Additionally, by transient transfection of HA-tagged 
SOS2-expressing plasmid into SKOV3 cells, the PLA 
results also provided structural evidence that SOS2 
bound to KRAS and could switch RAS-GDP (off) to 
RAS-GTP (on) as previously reported, similarly to 
SOS-RAS signaling [19] (Fig. 2C). Luciferase reporter 
assays demonstrated that transient transfection of 
miR-193a-3p could suppress 30-35% of luciferase 
signals in ERBB4-, SOS2- and KRAS-3’UTR, compared 
with a 45% reduction of the GRB7-3’UTR luciferase 
signal (Fig. 2D & 1G). Our previous findings have 
shown that GRB7 is a key modulator of MAPK/ERK 
signaling [9, 20]. Indeed, transient transfection of 
GFP/GRB7 could increase pERK1/2 levels in 
HEK293, SKOV3 and OVCA433 cells in a 
dose-dependent manner (Fig. 2E). In contrast, the 
reintroduction of miR-193a-3p could inhibit the 
protein levels not only of GRB7 but also of ERBB4, 
SOS2, KRAS and ERK (Fig. 2F). Taken together, these 
findings suggest that miR-193a-3p could target other 
factors, e.g., ERBB4, SOS2 and KRAS, in the 
MAPK/ERK signaling cascade, although it 
predominantly targeted GRB7 in ovarian cancer cells 
(Supplementary Fig. S3).  
Identification of DNA methylation leads to the 
downregulation of miR-193a-3p in ovarian 
cancer cells 
We next evaluated the expression levels of 
miR-193a-3p in clinical ovarian cancer samples (N = 
27). Interestingly, we found that the expression 
pattern of miR-193a-3p showed a stepwise decrease 
from the early to the late tumor stage (1 to 4) and from 
low to high grade (1 to 3) (P<0.0001) (Fig. 3A), 
supporting a remarkable loss of miR-193a-3p 
expression during the development and progression 
of ovarian cancer. Given that there was an inverse 
relationship between miR-193a-3p and GRB7 in 
ovarian cancer cell lines, it was of interest to evaluate 
their expression patterns in clinical samples. 
Immunohistochemistry (IHC) and in situ 
hybridization (ISH) were performed using a 
commercial human ovarian cancer tissue array 
(OVC1021, Pantomics) to evaluate the expression of 
GRB7 and miR-193a-3p, respectively. The results 
demonstrated that low expression of miR-193a-3p was 
significantly correlated with high expression of GRB7 
(N=97, P=0.003) (Fig. 3B) (Table 1). Notably, the low 
expression of miR-193a-3p (<4-fold) was significantly 
associated with advanced-stage cancers (P=0.048) 
(Fig. 3B) (Table 1). However, there was no significant 
correlation between the low level of miR-193a-3p and 
tumor grading or metastasis (Table 1). These findings 
indicated that the loss of miR-193a-3p led to a high 
expression level of GRB7 during ovarian cancer 
development.  
We next investigated the molecular mechanisms 
leading to the downregulation of miR-193a-3p in 
ovarian cancers. As the miR-193a-3p precursor is 
located on chromosome 17q11.2, where loss of 
heterozygosity (LOH) is rare in ovarian cancer [21, 
22], we therefore examined the range and content of 
miR193a-3p expression under the control of DNA 
methylation. Upon treatment with a demethylating 
agent, 5-Aza-dc (5 µM for 4 days), and evaluation by 
qPCR, the expression of miR-193a-3p was found to be 
upregulated in all the tested ovarian cancer cell lines 
(Fig. 3C). A further in-depth investigation using 
methylation-specific PCR (MS-PCR) analysis 
confirmed the silencing of miR-193a-3p in the above 
cell lines with hypermethylation of the miR-193a-3p 
promoter (Supplementary Fig. S1) (Fig. 3D). Indeed, 
pyrosequencing analysis showed a progressive 
increase in DNA methylation with a higher tumor 
stage (*P=0.0345 and **P=0.011) (Fig. 3E). However, 
there was no significant relationship between the 
methylation level and the tumor grade, confirming 
the IHC data showing that the downregulated 
miR-193a-3p was correlated with ovarian cancer 
development. Taken together, these findings 
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suggested that the loss of miR-193a-3p was due to 
epigenetic alterations during the development of 
ovarian cancer. 
 
 
Figure 2. MiR-193a-3p targets not only GRB7, but other key factors along MAPK/ERK signaling pathway in ovarian cancer cells. (A) The Venn diagram displays 77 common 
putative targets of miR-193a-3p predicted from the three algorithms, miRDB, miRanda and TargetScan Human 5.2, including three putative targets, ERBB4, KRAS and SOS2, 
involved in the MAPK/ERK signaling pathway. (B) Functional annotation analysis using the DAVID functional annotation tool (http://david.abcc.ncifcrf.gov/) showing the main 
signaling pathways associated with these 78 common targets of miR-193a-3p. (C) Duolink proximity ligation assay (PLA) with fluorescence and confocal microscopy showing the 
interactions between GRB7 and SOS2 and between GRB7 and KRAS (red dots) by transient transfection of GRB7-expressing plasmid (Upper). Anti-Myc, anti-SOS2 and 
anti-KRAS were used to detect Myc-tagged GRB7 and endogenous SOS2 and KRAS. Transient transfection of HA-SOS2 also showing the interaction between SOS2 and KRAS 
(red dots) using PLA and anti-HA as well as anti-KRAS (Lower). Scale bar, 20 µm. n = 3 independent experiments. (D) Relative luciferase activity of luciferase reporters with 
wild-type ERBB4, SOS2 and KRAS 3‘UTRs co-transfected with miR-193a-3p. (E) Western blot analysis showing that transient transfection of GFP/GRB7-expressing plasmid 
profoundly elevated ERK activity in HEK293, SKOV3 and OVCA433 cells. (F) Western blot analysis indicating that transient transfection of pmR-ZsGreen1-miR-193a-3p reduced 
the expression of GRB7, ERBB4, SOS2, KRAS and pERK1/2 in SKOV3 cells. Cell lysates of all the above cell transfectants were harvested 24 h after cell transfection. 
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Table 1. Clinico-pathological correlation of the expression of 
miR193a-3p in an ovarian cancer tissue array (OVC1021). The 
4-fold and 3-fold cut-off points of miR-193a-3p and GRB7, 
respectively, were determined by ROC analysis. 
Parameters n(=97) miR-193a-3p expression 
≤ 4-fold >4-fold p 
Grade     
Low (1+2) 50 31 (62%) 19 (38%)  
High (3) 46 37 (80%)  9 (20%) 0.071 
Stage     
Early (1) 48 29 (60%) 19 (40%)  
Late (2+3) 49 39 (80%) 10 (20%) 0.048* 
Metastasis     
Yes 24 20 (83%) 4 (17%)  
No 73 48 (66%) 25 (34%) 0.127 
GRB7     
≤ 3 folds 38 20 (53%) 18 (47%)  
> 3 folds 59 48 (81%) 11 (19%) 0.003* 
 
MiR-193a-3p suppresses ovarian cancer cell 
growth and migratory/invasive capacities 
Since aberrant activation of the MAPK/ERK 
signaling pathway plays key roles in numerous 
oncogenic processes [23, 24], we postulated that 
re-expression of miR-193a-3p could impede the 
activities of this signaling and its associated oncogenic 
capacities. Thus, we generated stable 
miR-193a-3p-expressing transfectants in SKOV3 and 
OVCA433 cells, and the expression levels were 
checked by qPCR analysis, while the expression levels 
of GRB7 were tested by Western blot analysis (Fig. 
4A). Simultaneously, their cellular functional effects 
were compared. As expected, re-expression of 
miR-193a-3p could markedly inhibit cell proliferation 
by 20-25% in SKOV3 (P<0.05) and OVCA433 cells 
(P=0.0012) (Fig. 4B). Similarly, miR-193a-3p also 
exhibited suppressive effects on the migratory ability 
by 65-80% (P<0.001) and on invasive ability by 60-80% 
(P<0.001) in SKOV3 and OVCA433 cells using 
Transwell cell migration/invasion assays (Fig. 4C). 
These data implied that re-expression of miR-193a-3p 
could suppress MAPK/ERK signaling, including 
GRB7, while mediating cell proliferation and 
migration/invasion capacities in ovarian cancer cells.  
Knockdown of GRB7 imitates the effect of 
miR-193a-3p on the inhibition of ovarian cancer 
oncogenic capacities 
To examine the critical role of GRB7 in 
MAPK/ERK oncogenic signaling in ovarian cancer 
cells, we employed a shRNAi approach to knock 
down endogenous GRB7 in SKOV3 ovarian cancer 
cells. Western blot analysis showed that depletion of 
GRB7 by shRNAi caused a >60% loss of endogenous 
GRB7 in SKOV3, accompanied by a reduction of the 
pERK1/2 level (Fig. 5A). However, this reduction was 
lower than that of the ectopic expression of 
miR-193a-3p (Fig. 2F). Knockdown of GRB7 also 
remarkably inhibited cell proliferation by ~40% 
(P=0.0024) (Fig. 5B) and cell migration capacity by 
95% (P<0.0001), as well as cell invasion capacity by 
45% (P=0.005) (Fig. 5C). We further examined the 
functional effect of GRB7 in ovarian cancer cells in vivo 
by administering an intraperitoneal (i.p.) injection of 
GRB7-knockdown SKOV3 cells (Fig. 5D). Reduced 
numbers of tumor nodules were detected in the 
GRB7-knockdown SKOV3 group compared with the 
control (P=0.0086) (Fig. 5D). Consistent with our 
previous studies [9, 20], these findings confirmed that 
GRB7 had a tumorigenic effect on ovarian cancer cells. 
Induced expression of miR-193a-3p suppresses 
ovarian cancer growth and tumor colonization 
To extend the study of the precise functional role 
of miR-193a-3p in the tumor growth and progression 
of ovarian cancer, we introduced a doxycycline 
(Dox)–inducible system, pT-193a, that allows the 
induction of miR-193a-3p by the addition of Dox in a 
highly metastatic cell line, SKOV3 [25, 26]. qPCR 
analysis revealed increased expression of miR-193a-3p, 
and the maximum expression was achieved 
(3.7-3.9-fold) on Day 4 (Fig. 6A). Consistent with this 
observation, the induced expression of miR-193a-3p 
was able to inhibit the expression level of GRB7 in a 
time-dependent manner, with the highest suppression 
observed on Day 4 (Fig. 6B). The XTT cell proliferation 
assay showed that Dox-induced miR-193a-3p could 
suppress cell growth by >40% by compared with the 
controls ± Dox or miR-193a-3p-inducible SKOV3 cells 
without Dox induction (P<0.001) (Fig. 6C). Moreover, 
using Transwell cell migration/invasion assays, we 
demonstrated that Dox-induced miR-193a-3p 
expression significantly attenuated cell 
migration/invasion capacities by more than 50% 
compared with the controls (P=0.008 and P=0.002) 
(Fig. 6D). These data support the notion that the loss 
of cell growth or cell migration/invasion capacities is 
attributed to the re-expression of miR-193a-3p. 
Furthermore, we examined the functional role of 
miR-193a-3p in ovarian cancer cells in vivo by 
intraperitoneal (i.p.) injection of miR-193a-3p-inducible 
SKOV3 cells into nude mice. When palpable tumors 
were formed on Day 20, miR-193a-3p was induced by 
administration of Dox in water (Fig. 6E). After 40 days 
of Dox administration to the water, all the mice were 
healthy. However, we observed an almost absence or 
a trace number of tumor nodules disseminated in the 
peritoneum and other organs in the peritoneal cavity 
of nude mice that received the Dox-containing water 
(Fig. 6F). When compared with the GRB7-knockdown 
system, tumor size and number of tumor nodules 
were significantly reduced in the mice with 
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Dox-induction of miR-193a-3p (P=0.0001) (Fig. 6F). 
These findings demonstrated a convergence such that 
the loss of miR-193a-3p could enhance oncogenic 
capacities via activation of MAPK/ERK signaling, 
facilitating tumor colonization of metastatic ovarian 
cancer in peritoneal metastases. 
 
 
Figure 3. DNA methylation leads to downregulation of miR-193a-3p during the tumor development and progression of ovarian cancer cells. (A) qPCR analysis 
revealing a stepwise decrease in miR-193a-3p expression from Stages 1 to 4 and Grades 1 to 3 in ovarian cancers. (B) Representative photographs showing an inverse 
correlation between miR-193a-3p and GRB7 expression by ISH and IHC analyses for serous subtype ovarian cancer samples (early stage = Stage 1 and Grade 2, and 
advanced stage = Stage 2 and Grade 3) on a commercial ovarian cancer tissue array (OVC1021, Pantomics). Scale bar, 100 µm. (C) The expression of miR-193a-3p 
could be restored in ovarian cancer cells upon treatment with 5-Aza-dc (5 µM) for 4 days. (D) Verification of miR-193a-3p promoter methylation by MS-PCR in 
ovarian cancer cells upon 5-Aza-dC treatment. Treatment with 5-Aza-dC (5 µM) for 3-4 days. (E) Pyrosequencing analysis showing a progressive increase in DNA 
methylation with the tumor stage (Upper) and grade (Lower) of ovarian cancers. 
 
Figure 4. Re-introduction of miR-193a-3p suppresses cell proliferation, cell migration and invasion capacities of ovarian cancer cells. (A) qPCR and Western blot 
analyses of miR193a-3p and GRB7 expression in stable miR-193a-3p-expressing SKOV3 and OVCA433 cells. SNORD48 was used as an internal control. (B) XTT 
proliferation assay, (C) Transwell cell migration and invasion assays showing that stable re-expression of miR-193a-3p inhibited cell proliferation rates, cell migration 
and invasion abilities of SKOV3 and OVCA433 ovarian cancer cells. 
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Figure 5. The functional role of GRB7 knockdown on cell proliferation, migration, invasion, and in vivo tumorigenicity. (A) Western blot analysis showing the levels 
of GRB7 knockdown (KD) and scrambled control (SCR) in SKOV3 cells. (B) XTT proliferation assay and (C) Transwell cell migration and invasion assays showing that 
knockdown of GRB7 inhibited cell proliferation, migration and invasion. (D) The 3-4-week-old female nude mice were i.p. injected with GRB7 knockdown or 
scrambled control SKOV3 cells and photographed on Day 60. Yellow arrows indicate the location of tumor nodules. The number of tumor nodules on the last day 
in each group are illustrated by bar charts (N=5). 
 
Discussion 
Aberrant upregulation of GRB7 is pervasive in 
many human cancers through the aberrant activation 
of MAPK/ERK signaling [1, 3, 9, 27]. Accumulating 
evidence indicates that targeting GRB7 is a promising 
approach to impede tumor aggressiveness [4-6]. 
However, most studies only characterized the 
functional roles and attempted to explore small 
molecules to block the activity of GRB7 and its 
downstream signaling [3, 7], yet the underlying 
molecular mechanisms leading to the upregulation of 
GRB7 in human cancer cells are relatively ill-defined. 
In this study, we provide the first evidence that 
miR-193a-3p plays a role as a tumor suppressor by 
directly targeting GRB7. Importantly, we show that 
the aberrant upregulation of GRB7 is attributed to 
epigenetically downregulating miR-193a-3p during 
tumor development and progression in ovarian 
cancer. Furthermore, we show that miR-193a-3p 
targets not only GRB7 but also other key components 
that modulate the MAPK/ERK signaling cascade in 
ovarian cancer cells. Interestingly, the re-introduction 
of miR-193a-3p exerted a stronger anti-tumor effect 
than just silencing GRB7 solely in ovarian cancer cells. 
Therefore, miR-193a-3p may be used as a 
miRNA-targeted therapeutic modality for ovarian 
cancer. 
GRB7 gene amplification has been documented 
in numerous human cancers, such as testicular 
neoplasms, esophageal squamous cell carcinoma 
(ESCC), breast and ovarian cancers [20, 27-29]. As 
GRB7 and HER2 are co-localized on the 17q12-21 
amplicon, the upregulation of both genes is correlated 
with more aggressive breast carcinomas [30]. GRB7 
was also co-amplified with another adjacent gene, 
ERBB2, in aggressive Barrett's carcinoma and gastric 
cancer [1, 31]. These findings suggest that the 
increased DNA copy number or amplicon is the main 
factor in the upregulation of GRB7 mRNA in human 
cancers. Two recent studies using 
immunohistochemical analysis (IHC) and 
fluorescence in situ hybridization (FISH) have shown 
that the protein level is positively correlated with the 
copy number of GRB7 [30, 32]. However, this is not 
the only conclusion based on the aberrant 
upregulation of GRB7 in human cancers. In this study, 
further in-depth investigations using Western blotting 
and qPCR analyses revealed a discrepancy between 
the protein and mRNA levels of GRB7, demonstrating 
the presence of aberrant post-transcriptional 
alterations of GRB7 in ovarian cancer cells. An in silico 
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study revealed that miR-193a-3p and miR-193b-3p are 
the main targets of human GRB7. Although 
miR-193a-3p and miR-193b-3p are located on 17q11.2 
and 16p13.12, respectively, both miRNAs share the 
same binding of the seed sequence in the 3’ UTR 
(length: 387) of the GRB7 gene and, therefore, able to 
interfere with the translational efficiency of GRB7 in 
ovarian cancer cells. Intriguingly, by comparing their 
expression patterns, we found that miR-193b-3p 
expression was relatively higher in both GRB7-low or 
high-expressing ovarian cancer cell lines, as well as 
HOSEs. Conversely, miR-193a-3p was frequently 
downregulated and was inversely correlated with the 
high expression of GRB7 in ovarian cancer cell lines. 
Among these ovarian cancer cell lines, we noted that 
some cells, e.g., OVCA429, A2780s and OVTOKO, 
should express higher levels of GRB7. However, 
extremely high expression of miR-193b-3p further 
reduced the levels of GRB7 in these cell lines. Based 
on the expression levels of GRB7 and both 
miR-193a-3p and miR-193b-3p in ovarian cancer cells, 
the frequently downregulated miR-193a-3p was 
deemed the main player in determining the 
expression of GRB7, while miR-193b-3p acted solely as 
a subsidiary to miR-193a-3p in further modulate the 
expression of GRB7. This finding is consistent with 
recent evidence showing that miRNAs work together 
as a team and co-modulate the expression of target 
genes in cellular processes or tumor progression [33]. 
Therefore, we focused our attention on deciphering 
the mechanism leading to the downregulation of 
miR-193a-3p and its role as a tumor suppressor-type 
miRNA in ovarian cancer.  
It is well known that miRNAs usually act as 
oncogenes or tumor suppressors to control many 
cellular events in tumor development and progression 
[34]. Similar to tumor suppressors, dysregulation of 
tumor suppressor-type miRNAs by epigenetic 
silencing is often observed in human cancers [35]. 
Hypermethylation of CpG islands of promoters is the 
major epigenetic aberration in the inactivation of 
these tumor suppressors [36]. In the present study, we 
found that miR-193a-3p was frequently 
downregulated in ovarian cancer cells. Accumulating 
evidence indicates that the miR-193a-3p precursor is 
located on chromosome 17q11.2, where the loss of 
 
 
Figure 6. DOX-induced miR-193a-3p inhibits cell migration and invasion in vitro and results in complete inhibition of tumor growth. (A) qPCR and (B) Western 
blot analysis showing induction of the expression of GRB7 by 1 µg/ml doxycycline (Dox) in a time-dependent manner. SNORD48 was used as an internal 
control. (C) XTT cell proliferation assay showing the effect of inducible miR-193a-3p on SKOV3 cells. (D) Transwell cell migration/invasion assays 
demonstrating the suppressive effect of inducible miR-193a-3p on the migration and invasion capacities of SKOV3 ovarian cancer cells. The induction of 
miR-193a-3p for cell proliferation and cell migration/invasion using 1 µg/ml Dox. (E) Schematic overview of miR-193a-3p expression in mice and its effect on the 
suppression of ovarian tumor growth in the intraperitoneal cavity of nude mice. (F) The 3-4-week-old female mice received an intraperitoneal injection (i.p.) 
of 1x106 miR-193a-3p-inducible SKOV3 cells. When palpable tumors formed on Day 20, all mice were treated with or without 2 mg/mL Dox in the drinking 
water until they were sacrificed on Day 60. Representative photographs of tumor nodules collected after induction of miR-193a-3p on Day 60. The table shows 
that only 1 out of 4 mice had tumor nodules in the Dox-inducible miR-193a-3p group, while all mice (4 out of 4) developed tumor nodules in the control group. 
The number of tumor nodules on the last day is illustrated for each group by bar charts (N=4). 
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heterozygosity (LOH) is rare in ovarian cancer [21, 
22]. We supposed that the downregulated 
miR-193a-3p was epigenetically silenced by DNA 
hypermethylation. As expected, hypermethylation of 
miR-193a-3p could be evidenced using 5-Aza-dC to 
mediate the restoration of miR-193a-3p, MS-PCR and 
pyrosequencing analyses on CpG islands of the 
promoter of the miR-193a-3p precursor. 
Correspondingly, CpG island hypermethylation of 
miR-193a-3p was observed in ovarian cancer clinical 
samples, and the progressive increase in the 
hypermethylation status was significantly correlated 
with the tumor stage of ovarian cancers. These data 
support not only the notion that DNA 
hypermethylation epigenetic silencing of miR-193a-3p 
but also epigenetic silencing of miR-193a-3p and 
upregulation of GRB7 actively occur during the tumor 
development and progression of ovarian cancers. 
Indeed, previous results showing the 
clinicopathological correlation of IHC and ISH 
analyses of miR-193a-3p and GRB7 support the above 
conclusion. 
Aberrant activation of MAPK/ERK signaling is 
critical for controlling cell proliferation, cell survival, 
metastasis and drug resistance in more than 85% 
human cancers [37]. Upon stimulation, this signaling 
pathway is initiated by upstream receptors, e.g., 
ErbBs that transmit the signals via GRB2, SOS and 
GRBs to activate the small GTPase RAS [38]. The 
active RAS recruits RAFs to the cellular membrane, 
where the activated RAFs phosphorylate MEK1/2, 
which in turn, activates ERK1/2 [38]. The 
phosphorylated ERK1/2 further phosphorylates RSK, 
and both are translocated to the nucleus to 
transcriptionally elevate the expression of numerous 
oncogenes with different oncogenic properties [39]. 
Mounting evidence has indicated that 
genetic/epigenetic alterations lead to the 
hyperactivation of MAPK/ERK signaling during 
tumor development and progression [40, 41]. Due to 
its pivotal role in cancers, this phenomenon has 
attracted large efforts by a number of research groups 
or pharmaceutical companies to explore inhibitors 
targeting different tiers of this cascade [42]. For 
example, the BRAF inhibitors vemurafenib 
(ZELBORAFTM, Roche-Genetech) and debrafenib 
(TAFINLARr, GSK), as well as the MEK inhibitors 
selumetinib (AZD6244, AstraZeneca/Array 
BioPharma) and trametinib (GSK1120212, GSK), are 
now in Phase II clinical trials for all tumors [38]. GRB7 
acts as a signaling adaptor that interacts with 
upstream receptors and modulates downstream 
signaling targets such as ERK [9]. Therefore, it is also 
an important targetable factor in human cancers. In 
fact, several research groups have attempted to 
explore novel and highly specific inhibitors to block 
the activity of GRB7 in human cancers [43, 44]. One 
promising inhibitor, the isanti-GRB7 peptide 
G7-18NATE, can suppress GRB7 binding to other 
activated tyrosine kinases [3, 7]. However, all these 
inhibitors are solely focused on GRB7. In the present 
study, we provide another avenue for the silencing of 
GRB7 and its cancer-associated signaling. We show 
that the knockdown of GRB7 and re-introduction of 
miR-193a-3p can remarkably suppress tumor cell 
growth and cell migration/invasion almost 
equivalently. This finding may be explained by the 
equivalent inhibitory effect on MAPK/ERK signaling 
activity. However, when comparing the effect on 
tumor growth in vivo, we showed that re-expression 
of miR-193a-3p provides stronger inhibition of tumor 
dissemination and colonization of ovarian cancer cells 
in the murine peritoneal cavity than depletion of 
GRB7 alone. This finding indicates that miR-193a-3p 
not only targets GRB7 but also other key components, 
ERBB4, SOS2 and KRAS, leading to a convergence of 
complete suppression in the aberrantly activated 
MAPK/ERK signaling pathway in human cancers 
including ovarian cancer [38, 45]. Moreover, due to 
the nature of miRNAs, one miRNA is able to target a 
network of multiple downstream signaling cascades. 
This signaling may be involved in promoting in vivo 
tumor growth, such as cell survival, angiogenesis and 
even cross-talk with the tumor microenvironment 
[46]. Indeed, using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) 
functional annotation bioinformatics microarray 
analysis, the results indicate that miR-193a-3p 
influences a greater spectrum of cancer-related 
signaling pathways than GRB7 alone. These findings 
pave the way for the development of miR-193a-3p as a 
miRNA-based therapeutic approach for ovarian 
cancer treatment. 
In summary, our results show that the 
upregulated GRB7 in some ovarian cancers is due to 
the epigenetic silencing of miR-193a-3p through DNA 
hypermethylation. Biochemical and functional 
analyses indicate that the re-introduction of 
miR-193a-3p profoundly inhibits tumorigenesis of 
ovarian cancer cells in vitro and in vivo by targeting 
GRB7 and the MAPK/ERK signaling cascade. These 
findings suggest that miR-193a-3p, a tumor suppressor 
miRNA, may potentially be employed in 
miRNA-based oncological therapies. 
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